查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179912

2022-2029 年全球sacral神經刺激市場

Global Sacral Nerve Stimulation Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球sacral神經刺激市場規模預計在預測期內（2022-2029 年）以 11.2% 的複合年增長率增長。

sacral神經調節 (SNM) 被數百萬患有膀胱過度活動症且對行為矯正和藥物治療有抵抗力的人使用。 SNM 的適應症包括尿瀦留、急迫性尿頻、急迫性尿失禁和大便失禁。

市場動態

在預測期內，老年人口的增長、市場開發的進步以及sacral神經刺激裝置的技術進步正在推動全球sacral神經刺激市場的發展。

世界上日益嚴重的老齡化人口正在推動全球市場的增長。

膀胱過度活動症 (OAB) 是多種症狀的混合體，會導致急迫和頻繁的排尿衝動，大多數人在夜間會出現更多的尿失禁。 膀胱過度活動症通常見於 65 歲以上的人群。 女性可以在較早的年齡患上 OAB，通常在 45 歲左右。 殘疾或外傷並不是尿失禁的唯一威脅。 隨著年齡的增長，自然會發生多種身體變化。 這些變化會影響身體，包括維持排洩的肌肉、器官和神經。 肌肉失去力量，一些神經失去能力，組織器官失去輕微的伸展能力。 因此，隨著老年人口的增長，對sacral神經刺激的需求也會增加，這將推動全球市場的增長。 舉例 例如，據世界衛生組織統計，2020年老年人口將達到10億，預計2030年將達到14億。 另據估計，到 2050 年，老年人口總數將比 2020 年翻一番，即 21 億。 同樣，2020 年至 2050 年期間，80 歲及以上人口預計將增加兩倍，達到 4.26 億。 因此，數據顯示，全球老齡化人口的增加將推動預測期內的市場增長。

設備的高成本阻礙了全球市場的增長。

然而，sacral神經刺激的高手術成本和產品成本阻礙了全球市場的增長。 舉例 例如，FDA批准並經臨床驗證的sacral神經刺激療法（Axonics Therapy）治療泌尿和腸道功能障礙的平均費用為30,000美元至40,000美元。

COVID-19 的影響

COVID-19 的爆發導致市場下滑，因為大多數非 COVID 治療援助已停止，以便為 COVID-19 患者提供醫療設施並減少 SARS-CoV-2 病毒的傳播。有一個負面影響 例如 例如，根據英國外科雜誌的報導，由於醫院服務的嚴重中斷，在 12 週的時間裡，大約有 2840 萬例擇期手術被取消或推遲。 此外，根據論文“關於 COVID-19 對泌尿外科服務影響的全球調查”（2020 年），女性尿失禁、陰囊良性疾病、膀胱結石、不孕症、前列腺增生、腎結石等門診患者據說處理它的診所受到大流行的很大影響。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 推進技術創新
      • 老年人口增加
      • 市場策略
    • 約束因素
      • 設備成本高
      • 相關風險
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 嵌入式社交網絡
  • 體外 SNS

第 8 章按應用程序類型

  • 大小便失禁
  • 急迫性尿失禁
  • 慢性肛裂
  • 其他

第 9 章最終用戶

  • 醫院和診所
  • 門診手術中心 (ASC)
  • 生命支持中心、療養院

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準

第12章公司簡介

  • 美敦力公司
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Boston Scientific Corporation
  • Jude Medical
  • Cyberonics
  • Neuropace
  • Synapse Biomedical
  • Uroplasty, Inc
  • Codman & Shurtleff, Inc.
  • Axonics Modulation Technologies, Inc.
  • Laborie, Inc

第13章 DataM

簡介目錄
Product Code: DMMD1675

Market Overview

The global sacral nerve stimulation market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 11.2% during the forecast period (2022-2029).

Sacral neuromodulation (SNM) is performed by millions of people with an overactive bladder which is refractory to behavioral modifications or pharmacotherapy. Indications for SNM enclose urinary retention, urgency frequency, urge incontinence, and fecal incontinence.

Market Dynamics

The growing geriatric population, increased market developments, and technological advancements in sacral nerve stimulation devices are boosting the global sacral nerve stimulation market during the forecast period.

The rising geriatric population globally is fueling the global market growth.

Overactive bladder (OAB) is a blend of manifestations that cause urgent and frequent impulses to urinate, the majority of individuals experience incontinence more at night. Overactive bladder is considered typical in people 65 and older. Females may have OAB at a younger age, normally about 45. Disorders or traumas are not the sole threats to incontinence. With the growing age, multiple physical shifts will transpire intrinsically. These modifications impact the body, including the muscles, organs, and nerves that maintain continence. Muscles will lose their strength, some nerves will not perform uup tothe mark, and tissue and organs will lose the little capacity to extend. Thus, with the growing geriatric population, the demand for sacral nerve stimulation will also increase, boosting the global market growth. For instance, according to WHO, the geriatric population accounted for 1 billion in 2020 and is assumed to reach 1.4 billion by 2030. Also, it is estimated that by 2050 the total geriatric population will double the population in 2020, i.e., 2.1 billion. Similarly, the number of individuals aged 80 years or older is anticipated to triple between 2020 and 2050 to surpass 426 million. Therefore, the mentioned data indicates that the growing global geriatric population will drive market growth during the forecast period.

The high cost of devices will hinder global market growth.

However, the high surgery and product costs of sacral nerve stimulation therapy is hindering the growth of the global market. For instance, the average expense of Axonics Therapy, an FDA-approved, clinically verified Sacral Neuromodulation solution to treat urinary and bowel dysfunction, costs between $30,000 and $40,000.

COVID-19 Impact.

The COVID-19 outbreak negatively affected the market since the majority of Non-COVID therapy assistance was halted to make the healthcare centers available for COVID-19 patients and lower the transmission of the SARS-CoV-2 virus. For instance, according to the British Journal of Surgery, about 28.4 million elective surgeries were withdrawn or delayed over 12 weeks because of extreme hospital service upsets. Moreover, according to an article titled "A Global Survey on the Impact of COVID-19 on Urological Services" (2020), outpatient clinics treating women's urinary incontinence, benign scrotal conditions, bladder stone, infertility, benign prostatic hyperplasia, and renal stone was majorly impacted by the pandemic.

Segment Analysis

The implantable SNS segment is predicted to have a high demand during the forecast period (2022-2029).

The implantable SNS segment is expected to grow at a high CAGR throughout the forecast period as new sacral stimulation implant devices are introduced into the market. For instance, in April 2022, the United States Food and Drug Administration (USFDA) granted clearance to the Axonics F15 device, permitting it to be implanted for 15 years to intercept the irregular nerve impulses associated with overactive bladder and fecal incontinence. Also, in 2022, Medtronic plc received approval from the United States Food and Drug Administration (USFDA) for its InterStim X, the next generation of the InterStim portfolio's recharge-free device. The InterStim system is a developed treatment choice and the most personalized system to provide sacral neuromodulation (SNM) therapy. Likewise, in February 2021, Contura introduced its newest SNM system, Bulkamid, to treat stress urinary incontinence (SUI). Bulkamid is considered one of the best-in-class & well-differentiated urethral bulking products for females suffering from stress urinary incontinence. Bulkamid has exhibited exceptional outcomes across clinical trials & practices, therefore illustrating a highly efficient first-line minimally invasive therapy for patients.

Similarly, in August 2020, the United States Food Drug and Administration (USFDA) approved Medtronic's InterStim Micro neurostimulator, and InterStim SureScan MRI leads for treating patients with bladder and bowel control disorders. The InterStim Micro neurostimulator is implied to treat patients with fecal incontinence, overactive bladders, and non-obstructive urinary retention through sacral neuromodulation therapy. Thus, owing to the increased product introduction, the implants segment is expected to dominate the global sacral neurostimulation market throughout the forecast period.

Geographical Analysis

North America is predicted to command the global sacral nerve stimulation market.

The North American sacral nerve stimulation market is estimated to grow at a high CAGR during the forecast period (2022-2029). The growing geriatric population, increased healthcare spending and the presence of a majority of key market players in this region contribute to the dominance of North America over the global sacral nerve stimulation market. For instance, according to the U.S. Census Bureau's latest estimates, more than 50 million people aged 65 and above live in the U.S., accounting for 16.5% of the population. Among other states, Florida has the largest ratio of senior citizens, about 21%, pursued by Maine with 20%. In contrast, Utah has the most inferior ratio of senior citizens, around 10.8%, followed by Alaska, with 11.1%. Also, California has the largest total geriatric population, more than 5.4 million, and after California, Florida has the second highest total geriatric population, at around 4.2 million. With baby boomers aging, state populations are witnessing an upsurge in citizens over 65. Moreover, according to the Centers for Medicare & Medicaid Services, national healthcare spending grew 2.7%, reaching $4.3 trillion in 2021, or $12,914 per person, which accounted for 18.3% of the Gross Domestic Product (GDP).

Furthermore, the presence of key market players such as Medtronic Plc, Boston Scientific Corporation, Jude Medical, Cyberonics, Neuropace, Synapse Biomedical, Uroplasty, Inc, Codman & Shurtleff, Inc, and Axonics Modulation Technologies, Inc., among others holding most of the global market; ensuring the growth of North American sacral nerve stimulation market at a high CAGR in the forecasted period.

Competitive Landscape

The significant players operating in the global sacral nerve stimulation market are Medtronic Plc, Boston Scientific Corporation, Jude Medical, Cyberonics, Neuropace, Synapse Biomedical, Uroplasty, Inc, Codman & Shurtleff, Inc, Laborie, Inc, and Axonics Modulation Technologies, Inc. The key players are embracing various approaches such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global growth of the medical supplies and equipment market. For instance, In July 2021, Neuspera Medical scored $65M in a series C funding round for a nerve-stimulating implant to treat overactive bladder.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. for sacral nerve stimulation contains InterStim systems: The InterStim systems implanted neurostimulators electrically stimulate the sacral nerve and are believed to normalize neural communication between the bladder and brain and between the bowel and brain.

The global sacral nerve stimulation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Advancements in Technology
      • 4.1.1.2. Growing Geriatric Population
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of devices
      • 4.1.2.2. Associated Risk
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Implantable SNS
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. External SNS

8. By Application Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 8.1.2. Market Attractiveness Index, By Application Type
  • 8.2. Urinary & Fecal Incontinence
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Urge Incontinence
  • 8.4. Chronic Anal Fissure
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Assisted Living Centers & Nursing Homes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Medtronic, Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Boston Scientific Corporation
  • 12.3. Jude Medical
  • 12.4. Cyberonics
  • 12.5. Neuropace
  • 12.6. Synapse Biomedical
  • 12.7. Uroplasty, Inc
  • 12.8. Codman & Shurtleff, Inc.
  • 12.9. Axonics Modulation Technologies, Inc.
  • 12.10. Laborie, Inc

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us